Cost-Effectiveness of Venetoclax Plus Obinutuzumab Versus Chlorambucil Plus Obinutuzumab for the First-Line Treatment of Adult Patients With Chronic Lymphocytic Leukemia: An Extended Societal View

Cost-Effectiveness of Venetoclax Plus Obinutuzumab Versus Chlorambucil Plus Obinutuzumab for the First-Line Treatment of Adult Patients With Chronic Lymphocytic Leukemia: An Extended Societal View

$1.00

Category:
Tags:

All your purchased models will be available under your account under “Dashboards”

Disease Area (Primary)

Chronic Lymphocytic Leukemia

Disease Area (Secondary)

–

First Developed

04/01/2023

Last Developed

04/01/2023

Software Used

Microsoft Excel

Model Sponsor

Government agency

Intervention

venetoclax

Model Validation Score

– %

Coming Soon In Phase II:  You will be able to pay a fee to download the CADTH Tool for your model which includes subaggregated scores.

Results

The base case resulted in a discounted ICER −49 928 EUR/QALY gained (with incremental negative costs and positive effects). None of the ICERs resulted from deterministic sensitivity and scenario analyses exceeded the chosen willingness-to-pay threshold of 20 000 EUR/QALY, and > 99% of the iterations in the probabilistic sensitivity analysis were cost-effective. VOI analyses showed a maximum expected value of eliminating all model parameter uncertainty of 183 591 EUR.

Conclusion

VenO being dominant over ClbO in treatment-naïve adult patients with CLL assuming a Dutch societal perspective

Source File(s)

Model:

Download Model File

Publication File:
Publication File 1:
Publication File 2:
Publication File 3:
Publication File 4:

No link submitted.

Download Publication 1

No link submitted.

No link submitted.

No link submitted.

CHEERS Checklist :
Document 2 :
Document 3 :
Document 4 :

No link submitted.

No link submitted.

No link submitted.

No link submitted.

Edit Model

Model Review

Only visible for the model owner

Summary
Validation Score

– %

Internal Comments

–

Full review
01 Model Built Reflective yes
02 Model Subgroups yes
03 Model Assesses all comparators yes
04 Model Incorporates costs yes
05 Model assesses all outcomes yes
06 Model structure validated by experts yes
07 Model aligns with or justifies deviation from previous models yes
08 Time in health states yes
09 Consistency with time in states yes
10 Clinical events extractable yes
11 Consistency with number of clinical events yes
12 Impact of adverse events yes
13 Consistency with adverse events yes
14 Life-years reported yes
15 Impact on mortality yes
16a Reasons for mortality differences yes
16b Reasons for mortality differences yes
16c Reasons for mortality differences yes
16d Reasons for mortality differences yes
17 Main driver of incremental life-years yes
18 Consistency with mortality rates yes
19 No technology-specific utilities used yes
20 Main driver of cost-effectiveness yes
21 Extrapolation methods identified yes
22 Adjustable time horizon yes
23 Double counting avoided yes
24 Surrogate vs final outcomes alignment yes
25 Flexibility for treatment effect waning yes
26 Access to deterministic and Monte Carlo results yes
27 Clear trace from inputs to outcomes yes
28 Macros used only for simulation/navigation (Excel) yes
29 QALY equivalence across technologies yes
30 Extreme effectiveness impact on QALY yes
31 Slight effectiveness impact on QALY yes
32 Increased mortality lowers QALYs yes
33 Reduced mortality increases QALYs yes
34 Increased baseline risk lowers QALYs yes
35 Reduced baseline risk increases QALYs yes
36 Zero mortality leads to equal life-years yes
37 Cost change affects only total costs yes
38 Utilities = 1 makes QALYs equal life-years yes
39 No discounting increases QALYs/costs yes
40 Higher discounting decreases QALYs/costs yes
41 Shorter time horizon lowers QALYs/costs yes
42 Inputs switchable across alternatives yes
43 Cost-QALY correlation across simulations yes
44 Strong cost correlation from Monte Carlo yes
45 Strong QALY correlation from Monte Carlo yes
46 Deterministic ≈ Probabilistic results yes
47 Backward trace from results to inputs yes
48 Backward trace from results to inputs yes
49 No use of non-transparent Excel functions yes
50 No hidden sheets, rows, or columns yes
51 No custom formulas inside VBA macros yes
52 Parameters persist after macros yes
53 Transparent input structure in single worksheet yes
Private internal comments –